Evidence map›Paper›PMID 35307963›Full record

ReviewCancer medicine2022

Retrospective analysis of adjuvant treatment for localized, operable uterine leiomyosarcoma.

Jomjit Chantharasamee, Karlton Wong, Pasathorn Potivongsajarn, Amir Qorbani, Neda Motamed, Sandra Brackert, Joshua Cohen, Bartosz Chmielowski, Anusha Kalbasi, Jianyu Rao and 2 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Current Treatment Options: Uterine Sarcoma.Current treatment options in oncology · 2024
    Review
  4. Management and prognosis of uterine sarcoma in elderly.Gynecology and pelvic medicine · 2024
    Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Jomjit ChantharasameeDivision of Hematology-Oncology, Department of Medicine, University of California, Los Angeles, California, USA.ORCID 0000-0002-1237-331X
Karlton WongDivision of Hematology-Oncology, Department of Medicine, University of California, Los Angeles, California, USA.
Pasathorn PotivongsajarnDepartment of Pathology, University of California, Los Angeles, California, USA.
Amir QorbaniDepartment of Pathology, University of California, Los Angeles, California, USA.
Neda MotamedDepartment of Pathology, University of California, Los Angeles, California, USA.
Sandra BrackertDivision of Hematology-Oncology, Department of Medicine, University of California, Los Angeles, California, USA.
Joshua CohenDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Los Angeles, California, USA.
Bartosz ChmielowskiDivision of Hematology-Oncology, Department of Medicine, University of California, Los Angeles, California, USA.
Anusha KalbasiDepartment of Radiation Oncology, University of California, Los Angeles, California, USA.ORCID 0000-0001-8692-1457
Jianyu RaoDepartment of Pathology, University of California, Los Angeles, California, USA.
Scott NelsonDepartment of Pathology, University of California, Los Angeles, California, USA.
Arun SinghDivision of Hematology-Oncology, Department of Medicine, University of California, Los Angeles, California, USA.
University of California, Los Angeles · USGynecologic Oncology Group · USSiriraj Hospital · TH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveCurrently, there is no standard adjuvant treatment protocol for localized uterine leiomyosarcoma (uLMS) as clinical trials to address this question have been retrospective, underpowered, or undermined by slow accrual rates. The aim of this study is to determine the benefit of adjuvant chemotherapy for uLMS.

methodsWe reviewed the medical records of localized uLMS patients who had underwent adjuvant therapy after upfront surgery between 2000 and 2020. The cases were blinded for review. We evaluated the influence of various clinical characteristics and different types of adjuvant therapies on specific outcomes.

resultsSixty-eight patients (median age: 50 years) were included for analysis. Forty of 68 (58.8%) patients received adjuvant chemotherapy +/- radiation therapy and 25 patients (38.6%) did not receive any adjuvant therapy. At a median follow-up time of 43.3 months, 45 patients (66.1%) had relapsed disease. The median disease-free survival (mDFS) for all patients was 23.1 months. Patients who received any adjuvant treatment (chemotherapy and/or radiation) trended toward a longer mDFS compared with those who did not receive any adjuvant therapy (29.7 vs. 14.1 months, p = 0.26). Patients who received adjuvant chemotherapy alone had a longer, but nonstatistically significant mDFS compared with those who did not receive any adjuvant treatment (22.2 vs. 14.1 months, p = 0.18). Additionally, univariate analysis found that tumor size large than 10 cm, and a mitotic rate >10/10hpf were independent prognostic factors for worse DFS.

conclusionsThough DFS was more favorable among those who received adjuvant therapy, it was not statistically significant, and thus based on this data adjuvant therapy for resected uLMS is still in question.

Indexed as

Chemotherapy, AdjuvantLeiomyosarcomaUterine NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansMiddle AgedPelvic NeoplasmsPrognosisRetrospective Studiesleiomyosarcomaoperableuterine leiomyosarcomauterine sarcoma

Identifiers

PMID35307963
PMCPMC9359871
OpenAlexW4220840887

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.